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TNFa/cachectin, released by monocytes/macrophages in response to bacterial en-
dotoxin (LPS), has been implicated as a principal mediator in endotoxic shock in
experimental animals (1). We have previously demonstrated a strong association be-
tween the presence of TNFa in serum and septic shock, and we have shown that
patients with serum concentrations ofTNFa exceeding 140 pg/ml invariably died (2).
IL-6 (also called IFN-ß2, 26-kD protein, B cell stimulatory factor 2, and hybridoma
growth factor) stimulates growth and differentiation of various lymphoid cells (3),
and induces the production of acute-phase proteins in cultured liver cells (4) . Pa-
tients receiving renal transplants have elevated serum levels of IL-6 (5) and TNF
(6). The biological activities of IL-6 are not yet completely uncovered, but appear
to overlap with those of TNF-a and another cytokine, IL-1 (4, 7) .
In contrast to the marked lethality associated with TNFa in septic shock, TNFa
is tolerated when administered to humans in clinical trials. Furthermore, the lethal
effect of TNFa in mice is potentiated by IL-1 (8) and by LPS (9). This suggests
that the deleterious effect associated with TNFa in human septic shock is not caused
by TNFa alone, but by TNFa in cooperation with other factors.
In this study we demonstrate that IL-6 and IL-1 are released into serum, and
coexist with TNFa and LPS in the systemic circulation during the initial phase of
meningococcal septic shock. High serum levels of IL-6 were associated with fatal
outcome, and .IL-1 was exclusively detected in patients who had high serum levels
of IL-6, TNFa, LPS, and a rapid fatal outcome.
Materials and Methods
Patients.
￿
We studied 79 patients (43male, 36 female, aged 1-93 yr) admitted to the university
hospitals in Bergen, Oslo (Ullevál) and Trondheim during 1981-86. The clinical diagnosis
ofmeningococcal disease was confirmed bacteriologically (72 patients) or serologically. Blood
was drawn on admission to hospital, and, from 9 patients with septic shock, also at intervals
during the initial 72 h of hospitalization. Serum/plasma samples were stored at -70°C.
Patients were considered to have septic shock if systolic blood pressure 470 mm Hg (pa-
tients,412 yr old), or 4100 mm Hg (>12 yr old). Patients with blood pressure above these
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limits, and positive blood cultures were considered to have bacteriaemia. Meningitis was defined
as >10s cells/liter cerebrospinal fluid, or back rigidity.
Assay for IL-6.
￿
IL-6 was determined by the IL-6-dependent mouse hybridoma cell line
B13.29 clone B9, as described (10). Serial dilutions of the test sample were incubated for 72 h
with IL-6-dependent cells. Viability was measured in a colorimetric assay with a tetrazolium
salt (Sigma Chemical Co., St. Louis, MO), as described (11). rIL-6 (12) was included as a
standard. The detection limit of the assay was 15-20 pg rIL-6/ml serum. An antiserum to
rIL-6 neutralized -400 ng rIL-6/ml antiserum (gift from Dr. W. Fiers, University of Ghent,
Belgium). The IL-6 activity in the samples was completely neutralized by this antiserum.
Assayfor IL-1 and IL-2.
￿
IL-1 was determined by an assay as described by Conlon (13)
with modifications. The subclone B of the LBRM-33-1A5 cells produces IL-2 upon activa-
tion with IL-1 and PHA-P. The cells were incubated with mitomycin C (50 ug/ml) (Sigma
Chemical Co.) for 30 min, and washed three times. 100 g1 of the LBRM-33-1A5 cells (5 x
10' cells/ml) was added to each well of a 96-well microplate with PHA-P (1 :2,000) (Difco
Laboratories, Detroit, MI) and serial dilutions of test sample. After 24 h, IL-2-dependent
HT-2 cells were added to each well (104 cells/well), and cell proliferation was determined
24 h later by the incorporation of ['H]thymidine (Amershamn Inc., Amersham, UK)
(1 gCi/well). Purified natural human IL-1 (Genzyme Corp., Boston, MA) was included as
a standard (units as specified by Genzyme Corp.). The sensitivity ofthe assay was 0.02 U/ml
serum. Antiserum against rIL-la and rIL-lß had previously been raised in sheep (gift from
Dr. A. Shaw, Glaxo, Geneva, Switzerland), and neutralized at least 20 wg/ml of rIL-la (Glaxo)
and at least 2 gg/ml of rIL-lß (Glaxo). The IL-1 activity in the patient samples was com-
pletely neutralized by a mixture of antiserum to rIL-la and antiserum to rIL-1ß.
IL-2 activity was determined by adding dilutions of test samples and rIL-2 (Genzyme)
to the HT-2 cells in a 96-well microplate. After 24 h, viability was measured in a colorimetric
assay with a tetrazolium salt (11). The detection limit of the assay was about 6 U/ml serum.
Assaysfor TNF-a and TNF-ß.
￿
TNFa was determined by its cytotoxic effect on the fibrosar-
coma cell line WEHI 164 clone 13, as described (14). rTNF-a (Biogen, Cambridge, MA and
BASF/Knoll, Ludwigshafen, FRG) were included as a standard. The detection limit of the
assay was 2-3 pg rTNFa/ml serum. An antiserum to rTNF (neutralizing capacity, 600 ng
rTNFa/ml) (14) completely neutralized the TNFa activity in the serum samples.
The WEHI 164 clone 13 cell line is also sensitive to rTNFP. The addition of a polyclonal
antiserum against rTNF0 (Biogen) had no effect on the cytotoxicity in the serum samples.
Assayfor LPS . LPS was determined in heparinized plasma by the limulus amebocyte ly-
sate test, as described (15). LPS from Escherichia coli (B 5505 ; Mallinckrodt Inc., St. Louis,
MO) were included as a standard. The detection limit of the assay was 25-30 pg/ml plasma.
Assayfor IFN-y .
￿
IFN-y was determined by ELISA as described elsewhere (16), and the
detection limit of rIFN-y (Genetech Inc., South San Francisco, CA) was 0.4 ng/ml serum.
Results
IL-6 in Serum.
￿
IL-6 was detected in 69 of the 79 admission serum samples (Fig.
1 a). The median serum level of IL-6 was -1,000 times higher in patients with septic
shock (189 ng/ml) than in patients with meningitis (0.2 ng/ml), bacteriaemia (0.2
ng/ml), or combined septic shock and meningitis (0.2 ng/ml). Serum levels in 15
healthy controls were below 0.05 ng/ml (data not shown). 11 of 21 patients with IL-6
levels >3.0 ng/ml died, whereas all 58 patients with levels at <3.0 ng/ml, survived.
All four patients with serum IL-6 levels >750 ng/ml died (Fig. 1 b).
IL-1 in Serum.
￿
IL-1 was detected in 3 of 20 serum samples tested. These three
patients had septic shock and the most rapid fatal courses of the patients who died
(Table I).
Levels of Cytokines and LPS in Individual Patients.
￿
Admission plasma/serum levels
of LPS, TNFa, IL-1, and IL-6 were recorded in 10 patients with septic shock (Table
1). Patients with high levels of LPS seemed to have high levels of TNF-a (r = 0.87,
p = 0.001), IL-6 (r = 0.94, ;6 = 0.0002), presence of IL-1 in serum (r = 0.86, p =335
Meningitis
￿
Septic
￿
Septic shock Bacterissmia
shock meningitis
"
￿
Detection limit for IL-8
Survived
￿
Died
FIGURE 1.
￿
Serum levels of IL-6 on admission in patients with meningococcal disease (a), and
relation between serum levels of IL-6 and outcome (b). Horizontal bars denote median values.
0.006), and fatal outcomes. TNFa in serum in the remaining 69 patients has previ-
ously been reported (2), and was included in the calculation ofthe positive correla-
tion (r = 0.62, ß = 0.0001) between the levels ofTNFa and IL-6 in admission serum
samples. The data indicate that the induction of IL-6, IL-1, and TNFa in human
septic shockis related, and that the common activation ofthesecytokines isassociated
with fatal outcome.
IL-2, IFN-y, and TNF0 were not detected in any of the samples.
Kinetics ofIL-6 and TNF-a.
￿
The kinetics ofproduction and elimination of IL-6
and TNFa during septic shock were studied in samples consecutively drawn from
nine of the patients included in TableI (data from five patients are shown in Fig.
2). The peak concentration ofTNFa occurred before (eight patients), or shortly
after (one patient) admission to hospital, whereas the peak concentration of IL-6
was detected 1-4 h after admission in five ofeight patients (four patients shown).
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TABLE I
Plasma/Serum Levels of LPS and Cytokines in Patients with
Meningococcal Septic Shock
Plasma or serum were collected on admission to hospital .
The results show that TNFa is released into serumbefore IL-6 in septic shock, and
that the levels of IL-6 are , 104 times higher than those of TNFa.
TNF-a was eliminated from the circulation at a constant rate in five of nine pa-
tients (four patients shown in Fig. 2); the half-life of TNF-a was calculated to be
70 ± 11 min (mean ± SD, n = 5). In the remaining four patients, additional TNF-
a was released into the circulation after an initial decline of the serum concentra-
tion (one patient shown). Detectable amounts of TNF-a were present in serum for
3-5 h after admission in five patients, and for up to 18 h in four patients. IL-6 was
FIGURE 2.
￿
Production and elimination of IL-6 (") and TNF-a (O) in meningococcal septic
shock. Asterisk indicates detection limit for TNF-a; 0 is point of time for admission to hospital.
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(hours after
admission) LPS
ng/ml
TNF-a
Pglml
IL-1
U/ml
IL-6
ng/ml
1/3 300 30,000 4.6 2,400
6 170 600 0.05 1,731
9 12 .0 78 0.15 918
39 10.5 300 <0.02 300
Survived 3 .8 65 <0.02 666
Survived 2.8 7 ND 81
Survived 2.8 33 <0.02 189
Survived 2.7 33 <0.02 165
29 1 .8 22 ND ND
Survived 0.8 13 <0.02 660WAAGE ET AL.
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eliminated from the circulation at a constant rate in seven of eight patients. The
half-life ofIL-6 was calculated to be 103 ± 37 min (mean ± SD, n = 6, thehalf-life
in one patientin Fig. 2 was 8 h, and was excluded from this calculation). Detectable
amounts of IL-6 were present in serum for up to 36 h.
Discussion
The study demonstrates that IL-6 and IL-1 are released into serum in patients
with meningococcal septic shock, and that high levels ofIL-6 and presence ofIL-1
are associated with fatal outcome.
Evidence has been given that TNFa is implicated as a mediator in septic shock
(1), whereas the role of IL-6 in septic shock is so far unclear. However, the relation
between levels of IL-6 and fatal outcome found in the present study is similar to
that previously demonstrated for TNFa (2), and opens the possibility that IL-6,
either by itself, or by interactions with TNFa, IL-1, or LPS, is involved in the patho-
genesis of the shock.
Recent studies have shown that IL-1 (8) and LPS (9) potentiate the lethal effect
of TNFa in mice. The three patients with high levels of LPS, TNFa, IL-6, and
detectable levels of IL-1 in serum, rapidly died, and emphasize that combinations
of LPS and cytokines may be particularly potent in producing lethal shock also in
humans.
The relation between the levels of IL-6, IL-1, and TNFa demonstrated in this
study, indicates that the induction mechanisms of these cytokines in septic shock
are related. In experimental animals, injection ofLPS induces release ofTNFa and
IL-6 after 1-2 h, whereas injection of TNFa induces release of IL-6 after N7 h
(Shalaby, R., and A. Waage, manuscript in preparation). Both TNF-a and IL-1 in-
duces the release of IL-6 by endothelial cells (Shalaby, R., A. Waage, and T. Es-
pevik, submitted for publication). In human septic shock, there may consequently
be multiple routes of induction of IL-6. The time interval between the release of
TNF-a and IL-6 demonstrated in our study, suggests that TNFa is a stimulator
of the IL-6 production in human septic shock.
Our study demonstrates that a complex pattern ofcytokines exists in the circula-
tion during the initial phase of septic shock, and emphasizes that the pathogenesis
ofthe shock should be analyzed not only with respect to TNFa, but also in terms
of interactions between IL-6, IL-1, TNFa, and LPS.
Summary
Serum samples from patients with meningococcal disease were examined for the
presence ofIL-6, TNFa, and LPS. Median serum concentration ofIL-6 was 1,000
times higher in patients with septic shock (189 ng/ml) than in patients with bacteri-
aemia, meningitis, or combined septic shock and meningitis. 11 of 21 patients with
serum levels >3.0 ng/mldied, whereas all 58 patients with serum levels at <3.0 ng/ml,
survived. All four patients with serum IL-6 levels >750 ng/ml, died. IL-1 was de-
tected in serum from three patients who also had high serum levels ofIL-6, TNFa,
and LPS, and rapidly fatal courses. IL-6 appeared to be released into serum later
than TNFa, and was detected in serum for up to 36 h. The half-life of IL-6 and
TNFa was calculated to be 103 ± 27 min and 70 t 11 min, respectively. These
data indicate that a complex pattern ofcytokines exists in serum from patients with
meningococcal septic shock, and that the release of IL-6 and IL-1, in addition to
TNFa, is associated with fatal outcome.33 8
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